Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Johnson & Johnson : Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:32pm CEST

Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP Reports

By a News Reporter-Staff News Editor at Women's Health Weekly -- Plaintiffs pursuing talcum powder lawsuits in Missouri state court claim that newly unsealed documents show that Johnson & Johnson has known since the 1970s that its talc-based powders contained asbestos fibers, which could increase the risk of ovarian cancer in women who used the products for daily feminine hygiene. (Case No. 1522-CC10417, Circuit Court, City of St. Louis, Missouri)

"Our Firm is representing women who allegedly developed ovarian cancer due to Johnson & Johnson's talcum powder products. These documents are of great interest to our clients, and we will continue to monitor the Missouri litigation for any other developments that could impact their claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with Johnson & Johnson'sBaby Powder and Shower-to-Shower products (see also Bernstein Liebhard Llp).

Keywords for this news article include: Talc, Asbestos, Oncology, Gynecology, Legal Issues, Silicic Acid, Women's Health, Silicon Dioxide, Silicon Compounds, Inorganic Chemicals, Magnesium Silicates, Risk and Prevention, Mixed Ovarian Cancer, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12:26pJOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
AQ
12:01pJOHNSON & JOHNSON : Janssen Submits New Drug Application to FDA Seeking Approval..
AQ
05:32aMAILMYLENS.COM OFFERING THE BEST OF : Mailmylens.com is providing a variety of ..
AQ
09/19JOHNSON & JOHNSON : to Host Investor Conference Call on Third-Quarter Results
PR
09/19JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
PU
09/19PFIZER : Drug companies cheating countries out of billions in tax revenues, reve..
AQ
09/18JOHNSON & JOHNSON : Expert panel holds first meeting to decide compensation for ..
AQ
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
09/18JOHNSON & JOHNSON : Abbott, Johnson & Johnson, Merck, and Pfizer Depriving Count..
AQ
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
More news
News from SeekingAlpha
02:06pArvinas Holding Prepares Terms For $100 Million IPO 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/19My Quarterly Global Portfolio Update 
09/19Surviving The Geron Roller Coaster As An Investor 
09/18J&J files U.S. marketing application for erdafitinib for urothelial cancer 
Financials ($)
Sales 2018 81 257 M
EBIT 2018 24 952 M
Net income 2018 16 036 M
Debt 2018 11 280 M
Yield 2018 2,55%
P/E ratio 2018 20,74
P/E ratio 2019 17,94
EV / Sales 2018 4,78x
EV / Sales 2019 4,54x
Capitalization 377 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 144 $
Spread / Average Target 2,2%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.59%376 820
PFIZER20.13%253 595
NOVARTIS-0.80%216 184
ROCHE HOLDING LTD.-4.06%211 637
MERCK AND COMPANY24.36%186 114
AMGEN16.35%131 526